ECSP22008098A - Compuestos agonistas de gipr - Google Patents

Compuestos agonistas de gipr

Info

Publication number
ECSP22008098A
ECSP22008098A ECSENADI20228098A ECDI202208098A ECSP22008098A EC SP22008098 A ECSP22008098 A EC SP22008098A EC SENADI20228098 A ECSENADI20228098 A EC SENADI20228098A EC DI202208098 A ECDI202208098 A EC DI202208098A EC SP22008098 A ECSP22008098 A EC SP22008098A
Authority
EC
Ecuador
Prior art keywords
compounds
gipr
agonist compounds
useful
treatment
Prior art date
Application number
ECSENADI20228098A
Other languages
English (en)
Inventor
Andrea Renee Geiser
Hongchang Qu
John Lee
Jorge Alsina-Fernandez
William Christopher Roell
Lili Guo
Samantha Grace Lyons Keyser
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72145469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22008098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22008098A publication Critical patent/ECSP22008098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos que tienen actividad en el receptor de polipéptido insulinotrópico dependiente de glucosa (GIP) humano. La presente invención se refiere además a compuestos que tienen una duración de acción prolongada en el receptor de GIP. Tales compuestos pueden ser útiles en el tratamiento de la diabetes, que incluye diabetes mellitus tipo 2 ("T2DM"). Además, los compuestos pueden ser útiles en el tratamiento de la obesidad.
ECSENADI20228098A 2019-08-01 2022-02-01 Compuestos agonistas de gipr ECSP22008098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962881685P 2019-08-01 2019-08-01

Publications (1)

Publication Number Publication Date
ECSP22008098A true ECSP22008098A (es) 2022-03-31

Family

ID=72145469

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20228098A ECSP22008098A (es) 2019-08-01 2022-02-01 Compuestos agonistas de gipr

Country Status (23)

Country Link
US (3) US11254721B2 (es)
EP (1) EP4007593A1 (es)
JP (3) JP7230272B2 (es)
KR (2) KR20250065721A (es)
CN (2) CN114206915B (es)
AR (1) AR119471A1 (es)
AU (2) AU2020322784B2 (es)
CA (1) CA3145608A1 (es)
CL (1) CL2022000140A1 (es)
CO (1) CO2022000759A2 (es)
CR (1) CR20220020A (es)
DO (1) DOP2022000025A (es)
EC (1) ECSP22008098A (es)
IL (1) IL289463A (es)
JO (1) JOP20220024A1 (es)
MX (2) MX2022001137A (es)
MY (1) MY205796A (es)
PE (1) PE20220938A1 (es)
PH (1) PH12022550232A1 (es)
SA (1) SA522431576B1 (es)
TW (1) TWI764209B (es)
UA (1) UA129203C2 (es)
WO (1) WO2021021877A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US20220016215A1 (en) * 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AR124295A1 (es) * 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2022253202A1 (zh) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
KR20250057847A (ko) 2022-08-29 2025-04-29 일라이 릴리 앤드 캄파니 경구 전달용 조성물
KR102679905B1 (ko) * 2022-10-12 2024-07-02 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
US20260139314A1 (en) * 2022-10-12 2026-05-21 Seoul National University Hospital Composition and method for predicting sulfonylurea dependency using gipr marker
JP2026511611A (ja) * 2023-03-31 2026-04-14 イーライ リリー アンド カンパニー 悪心及び嘔吐を治療するための方法及び使用
CN116410298B (zh) * 2023-06-06 2023-08-11 诺博泰科(成都)生物科技有限公司 一种三激动多肽化合物及其盐、药用组合物、药剂和用途
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025161155A1 (zh) * 2024-02-04 2025-08-07 内蒙古博睿精创科技有限公司 一种长效glp-1多肽化合物、组合物及其应用
TW202615088A (zh) * 2024-06-14 2026-04-16 美商美國禮來大藥廠 用於改善胰島素敏感性之組合物及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP3212218B1 (en) * 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
AR103242A1 (es) * 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
AR110301A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
ES3068975T3 (en) * 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
US20220016215A1 (en) 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP3856768A2 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr

Also Published As

Publication number Publication date
US11254721B2 (en) 2022-02-22
JOP20220024A1 (ar) 2023-01-30
SA522431576B1 (ar) 2024-10-29
JP2023062068A (ja) 2023-05-02
AR119471A1 (es) 2021-12-22
WO2021021877A1 (en) 2021-02-04
TW202126680A (zh) 2021-07-16
AU2020322784B2 (en) 2025-01-30
US20240218031A1 (en) 2024-07-04
DOP2022000025A (es) 2022-03-15
AU2025203018A1 (en) 2025-07-17
CO2022000759A2 (es) 2022-02-07
JP7521027B2 (ja) 2024-07-23
KR102801905B1 (ko) 2025-05-02
JP2022544061A (ja) 2022-10-17
US11897926B2 (en) 2024-02-13
UA129203C2 (uk) 2025-02-05
MX2026002524A (es) 2026-04-01
CN114206915A (zh) 2022-03-18
NZ784648A (en) 2025-08-29
JP7230272B2 (ja) 2023-02-28
JP2024150523A (ja) 2024-10-23
PE20220938A1 (es) 2022-05-31
US20210032299A1 (en) 2021-02-04
EP4007593A1 (en) 2022-06-08
CA3145608A1 (en) 2021-02-04
AU2020322784A1 (en) 2022-02-03
CL2022000140A1 (es) 2022-09-30
IL289463A (en) 2022-02-01
TWI764209B (zh) 2022-05-11
MY205796A (en) 2024-11-13
PH12022550232A1 (en) 2023-01-04
MX2022001137A (es) 2022-02-16
KR20250065721A (ko) 2025-05-13
CN120040559A (zh) 2025-05-27
US20220127315A1 (en) 2022-04-28
CR20220020A (es) 2022-02-14
CN114206915B (zh) 2025-03-11
BR112022000027A2 (pt) 2022-05-24
KR20220028007A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
DOP2022000025A (es) Compuestos agonistas de gipr
MX2021000793A (es) Compuestos coagonistas de gip/glp1.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
UA118239C2 (uk) Сполука-коагоніст gip і glp-1
AR121093A1 (es) Compuestos coagonistas de gip / glp1
DOP2017000102A (es) Coagonistas de los receptores de glucagón y de glp-1
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
EA201170302A1 (ru) Процессированные аналоги глюкозозависимого инсулинотропного полипетида
PE20151770A1 (es) Compuesto peptidico
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
EA201291234A1 (ru) Аналоги глюкагона
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
ECSP17032341A (es) Coagonistas de los receptores de glucagón y de glp-1
TH2201000489A (th) สารประกอบ gipr-อะโกนิสท์
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1